NASDAQ:DCPH Deciphera Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $56.07 +3.50 (+6.66 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$52.77Now: $56.07▼$56.1750-Day Range$43.80MA: $46.30▼$52.5752-Week Range$31.37Now: $56.07▼$71.11Volume1.33 million shsAverage Volume306,679 shsMarket Capitalization$3.16 billionP/E RatioN/ADividend YieldN/ABeta1.84 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.85, Deciphera Pharmaceuticals has a forecasted upside of 28.1% from its current price of $56.07.Amount of Analyst CoverageDeciphera Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesDeciphera Pharmaceuticals has received 283 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDeciphera Pharmaceuticals has received 284 “underperform” votes. (Add your “underperform” vote.)Community SentimentDeciphera Pharmaceuticals has received 50.09% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote “Outperform” if you believe DCPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,966,578.00 in company stock.Percentage Held by InsidersOnly 3.81% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions74.63% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($5.24) to ($4.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 5.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCPH Previous Symbol CUSIPN/A CIK1654151 Webwww.deciphera.com Phone781-209-6400Debt Debt-to-Equity Ratio0.02 Current Ratio12.33 Quick Ratio12.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25 million Price / Sales126.45 Cash FlowN/A Price / Cash FlowN/A Book Value$10.71 per share Price / Book5.24Profitability EPS (Most Recent Fiscal Year)($4.48) Net Income$-192,260,000.00 Net MarginsN/A Return on Equity-43.12% Return on Assets-39.16%Miscellaneous Employees112 Outstanding Shares56,380,000Market Cap$3.16 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $56.07 +3.50 (+6.66 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DCPH News and Ratings via Email Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions How has Deciphera Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DCPH stock has increased by 26.2% and is now trading at $56.07. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Deciphera Pharmaceuticals? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals. When is Deciphera Pharmaceuticals' next earnings date? Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Deciphera Pharmaceuticals. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its earnings results on Tuesday, August, 4th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.34) by $0.14. View Deciphera Pharmaceuticals' earnings history. What price target have analysts set for DCPH? 13 brokerages have issued 1 year price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $49.00 to $91.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $71.85 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals. Who are some of Deciphera Pharmaceuticals' key competitors? Some companies that are related to Deciphera Pharmaceuticals include Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), CureVac B.V. (CVAC), GALAPAGOS NV/S (GLPG), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Myokardia (MYOK), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Allena Pharmaceuticals (ALNA), Vertex Pharmaceuticals (VRTX), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX). Who are Deciphera Pharmaceuticals' key executives? Deciphera Pharmaceuticals' management team includes the following people: Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55) When did Deciphera Pharmaceuticals IPO? (DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers. What is Deciphera Pharmaceuticals' stock symbol? Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH." Who are Deciphera Pharmaceuticals' major shareholders? Deciphera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.30%), ArrowMark Colorado Holdings LLC (2.78%), Orbimed Advisors LLC (2.00%), FMR LLC (1.44%), Artal Group S.A. (1.15%) and TimesSquare Capital Management LLC (0.99%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View institutional ownership trends for Deciphera Pharmaceuticals. Which major investors are selling Deciphera Pharmaceuticals stock? DCPH stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Deerfield Management Company L.P. Series C, Artal Group S.A., FMR LLC, ArrowMark Colorado Holdings LLC, Nicholas Investment Partners LP, Orbimed Advisors LLC, and Cormorant Asset Management LP. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, Patricia L Allen, and Thomas Patrick Kelly. View insider buying and selling activity for Deciphera Pharmaceuticals. Which major investors are buying Deciphera Pharmaceuticals stock? DCPH stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Candriam Luxembourg S.C.A., Avidity Partners Management LP, Healthcare of Ontario Pension Plan Trust Fund, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Man Group plc, and Nuveen Asset Management LLC. View insider buying and selling activity for Deciphera Pharmaceuticals. How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Deciphera Pharmaceuticals' stock price today? One share of DCPH stock can currently be purchased for approximately $56.07. How big of a company is Deciphera Pharmaceuticals? Deciphera Pharmaceuticals has a market capitalization of $3.16 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe. What is Deciphera Pharmaceuticals' official website? The official website for Deciphera Pharmaceuticals is www.deciphera.com. How can I contact Deciphera Pharmaceuticals? Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
